Mental Help Net
Diabetes
Resources
Basic InformationMore InformationLatest News
GAD Antibodies Linked to Increased Risk of DiabetesDiabetes Patients, Doctors May Have Different Health PrioritiesClosed-Loop Insulin Delivery Helps Young Diabetes PatientsGenome Mapped for Type 2 DiabetesClinical Trials Update: Feb. 2, 2010Tight Blood Sugar Control May Raise Risk of DeathSkipping Insulin May Not Be UncommonVictoza Sanctioned for Type 2 DiabetesInsulin Syringe Recalled Because of Defective NeedleStandards Revised for Diabetes Self-Management EducationDiabetes Patients May Be at Higher Risk for Lung DiseasesSleep Apnea Severity Linked to Glucose Control in DiabetesDiabetes Diary More Flexible Than Carbohydrate CountingMetformin May Worsen Peripheral NeuropathyNewly Identified Gene Variants Linked to DiabetesMore Adverse Events Noted With Stents in Diabetes PatientsArtificial Pancreas Prototype in Development for Type 1 DiabeticsClinical Trials Update: Jan. 11, 2010Disease Burden of Obesity Matches That of SmokingDiabetes Meds May Be Falling Through 'Doughnut Hole'Mouse Study Assesses Use of Tetracycline in DiabetesClinical Trials Update: Jan. 6, 2010Risk of Type 1 Diabetes in Offspring of Patients AssessedFat Hormone Controls Gene Linked to DiabetesMarkers Predict Kids' Risk of Diabetes as AdultsUse of A1C in the Diagnosis of Diabetes SupportedGenes May Put Black Americans at Risk for DiabetesLaser Deemed Best Treatment for Diabetic RetinopathyDeclines Found in Diabetes-Related Renal DiseaseEfficacy of Glyburide for Gestational Diabetes StudiedDrugs Not Linked to β-Cell Improvement in DiabetesNew Guidelines Urge A1C Test for Diabetes DiagnosisDiabetics Less Prone Now to End-Stage Kidney DiseaseHistory of Foot Ulcers Can Increase Mortality in DiabetesGlycemic Index Education Helps Manage Type 2 DiabetesClinical Trials Update: Dec. 22, 2009Parents Not Stressed by Child's Genetic Risk for DiabetesDiabetes Insight Could Lead to Better TreatmentsMouse Study Suggests Type 2 Diabetes Potential TreatmentWork-Related Stress May Raise Women's Diabetes RiskCoffee and Tea Intake Associated With Diabetes RiskComorbidity Affects Outcome of Glycemic Control in DiabetesTighter Blood Sugar Control Not Best for Some DiabeticsDiabetes Patients Report Many Hypoglycemic Driving EventsVariable A1C Linked to Renal Disease in Type 1 DiabetesStudy Explores Genetics of Microalbuminuria in DiabetesStudy Compares Cardiac, Death Risks of Diabetes DrugsDiabetes Drugs Go Head-to-Head in StudyDiabetes in Pregnancy Hikes Risk for Metabolic SyndromeCardiovascular Effects of Type 1 Diabetes in Youth Studied
Blog EntriesVideosLinks
Community

Talk about this issue in our mental health support community

Therapist Search
Find a Therapist:
 (USA/CAN only)

Use our Advanced Search to locate a therapist outside of North America.

Related Topics

Medical Disorders

Drug May Reverse Type 1 Diabetes Ocular Complications

HealthDay News
by -- Rick Ansorge
Updated: Nov 16th 2009

new article illustration

MONDAY, Nov. 16 (HealthDay News) -- In rats induced with type 1 diabetes, topical treatment with naltrexone hydrochloride (NTX), an opioid antagonist, reverses dry eye and restores corneal sensitivity, according to a study in the November issue of the Archives of Ophthalmology.

Ian S. Zagon, Ph.D., of the Pennsylvania State University in Hershey, and colleagues used streptozotocin to induce type 1 diabetes in rats. One group of rats received either NTX eye drops or sterile vehicle once only, while two other groups of rats received either NTX eye drops or sterile vehicle four times a day for one day or five days.

The researchers found that one drop of NTX once only or four times a day for one or five days normalized tear production and corneal sensitivity within one hour of administration. They also found that the effect on tear production persisted for as long as three days and that the effect on corneal sensation persisted for four to seven days.

"This would suggest the need for the initiation of clinical trials examining the safety and efficacy of this drug for ocular use," the authors write. "Moreover, it may be reasonable to evaluate the impact of NTX on other non-ocular complications of diabetes, such as peripheral neuropathy, and its role, if any, in the treatment of other disorders of corneal sensitivity and/or tear production."

Several authors reported the filing of a provisional patent on the use of opioid antagonists to treat dry eye.

Abstract
Full Text (subscription or payment may be required)

Follow us on Twitter!

Find us on Facebook!




Powered by CenterSite.Net